Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

BK7508 Pharmaceutical Companies

Not Yet Opened 09-25 16:00:00 AEST

662.84

-9.58

-1.43%

High672.50	Low660.77	Vol35.52M
Open672.37	D1 Closing672.43	Amplitude1.74%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O133.20M	T/O Rate--	Tradable Shares0.00
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":662.84216,"timestamp":1790315999734,"preClose":672.4254,"halted":0,"volume":35523295,"delay":0,"changeRate":-0.014252,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-9.583252,"latestTime":"09-25 16:00:00 AEST","open":672.37463,"high":672.49646,"low":660.7652,"amount":133201452,"amplitude":0.017446,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1790553600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1790294400000,1790316000000]],"turnoverRate":0.001412,"increases":6,"decrements":18,"flats":18,"marketCap":94992917156,"floatMarketCap":91800947375.875},"requestUrl":"/m/hq/s/BK7508/wiki","defaultTab":"wiki","newsList":[{"id":"2670707554","title":"Elite Australian Growth Stocks To Own In September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2670707554","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670707554?lang=en_us&edition=fundamental","pubTime":"2026-09-26 11:28","pubTimestamp":1790393289,"startTime":"0","endTime":"0","summary":"Rising long term bond yields have pushed borrowing costs higher, which puts pressure on many growth stocks that rely heavily on cheap debt. That makes financially healthier Australian growth stories more interesting right now. This screener focuses on businesses where analysts see strong earnings growth potential and balance sheets that can better handle higher rates. In this article, you will see three of the strongest candidates from that group.\nThe three Australian stocks highlighted below...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551730-choice1-card/1788960340613","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551730-choice1-card/1788960340613"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/elite-australian-growth-stocks-to-own-in-september-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/elite-australian-growth-stocks-to-own-in-september-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7043","DACE.AU","BK7096","ZYAU.AU","4DX.AU","BBOZ.AU","BK7508","VTHR","IOZ.AU","AGIX","AIPO","OZR.AU","BK7503","QFN.AU","ARTY","BK7094","MP1.AU","SLF.AU","IIGF.AU","GIVE.AU","OZF.AU","GEAR.AU","XJO.AU","E200.AU","IISV.AU","STW.AU","IMLC.AU","EIGA.AU","CHAT","NEU.AU","VAP.AU","BEAR.AU","XAO.AU","QTOC","VAS.AU","XKO.AU","QRE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670208384","title":"NASDAQ Trade Halt Halt News Pending at 07:50 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2670208384","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670208384?lang=en_us&edition=fundamental","pubTime":"2026-09-26 07:50","pubTimestamp":1790380200,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 07:50 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nAQN2MKW2S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK4139","IMMP","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669541554","title":"Paradigm Biopharmaceuticals to Return $2 Million of Funds to Obsidian Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2669541554","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669541554?lang=en_us&edition=fundamental","pubTime":"2026-09-24 14:12","pubTimestamp":1790230359,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  agreed to return the $2 million of funds it recently received from Obsidian Global under a fourth-tranche drawdown of its convertible note facility, according to a Thursday filing with the Australian bourse.The 2 million convertible notes issued in connection with the drawdown will be cancelled, and no premium, redemption amount, or other amount is payable by Paradigm under the arrangement, per the filing.The development follows the interim efficacy result for Paradigm's phase 3 trial of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis failing to reach the threshold required for the study to proceed.The company is reviewing data to better understand what impact that trial result will have on its financial position and future operations.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451310","title":"Paradigm Biopharmaceuticals Ltd-Agreement to Return US$2M to Obsidian","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669451310?lang=en_us&edition=fundamental","pubTime":"2026-09-24 13:25","pubTimestamp":1790227524,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUE2K4JSC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669341451","title":"Paradigm Biopharmaceuticals - 2 Mln Convertible Notes Issued in Tranche 4 Drawdown to be Cancelled","url":"https://stock-news.laohu8.com/highlight/detail?id=2669341451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669341451?lang=en_us&edition=fundamental","pubTime":"2026-09-24 13:25","pubTimestamp":1790227524,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUE2K4JSC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669379574","title":"Australia's Mesoblast Rises on FDA Approval for New Potency Assay for Commercial Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2669379574","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669379574?lang=en_us&edition=fundamental","pubTime":"2026-09-24 08:38","pubTimestamp":1790210283,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mesoblast rises on FDA approval for new potency assay for commercial Ryoncil** Shares of MesoblastMSB.AXrise as much as 5.1% to A$2.29, their biggest intraday pct gain since August 28","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nL4N45G01P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7067","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669432383","title":"Mesoblast - Receives FDA Approval for New Potency Assay for Commercial Ryoncil Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2669432383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669432383?lang=en_us&edition=fundamental","pubTime":"2026-09-24 07:52","pubTimestamp":1790207540,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUEBVRFV4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MESO","BK7501","BK7067","BK7508","MSB.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669459671","title":"3 ASX Growth Companies With Up To 15% Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2669459671","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669459671?lang=en_us&edition=fundamental","pubTime":"2026-09-24 03:08","pubTimestamp":1790190481,"startTime":"0","endTime":"0","summary":"As the Australian market opens with a modestly positive outlook, influenced by Wall Street's tech-driven gains and ongoing discussions around interest rates, investors are keenly watching how local technology stocks respond amidst broader economic uncertainties. In this environment, growth companies with high insider ownership can offer unique insights into potential long-term value creation, as insiders typically have a vested interest in the company's success and may provide stability amid...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/7131000-choice1-card/1788935066370","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/7131000-choice1-card/1788935066370"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/diversified-financials/asx-mfg/magellan-financial-group-shares/news/3-asx-growth-companies-with-up-to-15-insider-ownership","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/diversified-financials/asx-mfg/magellan-financial-group-shares/news/3-asx-growth-companies-with-up-to-15-insider-ownership","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7016","BK7023","BK7095","BK7094","FRS.AU","CBO.AU","VAP.AU","BK7142","ZYAU.AU","BK7062","AEM.AU","AV1.AU","MFG.AU","XKO.AU","IMLC.AU","XJO.AU","BK7141","BEAR.AU","BK7501","QRE.AU","AR1.AU","BK7508","SLF.AU","QFN.AU","DXN.AU","BBOZ.AU","BK7104","PDI.AU","OZF.AU","EIGA.AU","IIGF.AU","IOZ.AU","BK7110","P1E.AU","BK7017","DACE.AU","WZR.AU","BK7043","BK7096","IISV.AU","STW.AU","XAO.AU","GEAR.AU","AYA.AU","OZR.AU","E200.AU","GIVE.AU","SPL.AU","SKS.AU","VAS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669091482","title":"Hexcel Poised to Continue to Benefit From its Widebody Aircraft Exposure, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669091482","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669091482?lang=en_us&edition=fundamental","pubTime":"2026-09-23 23:29","pubTimestamp":1790177377,"startTime":"0","endTime":"0","summary":"Hexcel (HXL) is poised to continue to benefit from its widebody aircraft exposure, as current widebody fleet dynamics support a strong aftermarket outlook, RBC Capital Markets said in a Tuesday note.R","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOEG","NATO","BK7508","LU0205193047.USD","MISL","PPA","BK4551","BZZ","ROKT","BK4187","LU1435385759.SGD","BK7067","BOEU","HXL","BA","LU0162691827.USD","IDEF","LU0240877869.USD","LU0053671581.USD","LU0205194284.USD","BK4585","BOED","ITA","LU0240878834.USD","BK4588","LU0072461881.USD","IE000M9KFDE8.USD","HXL.AU","LU1429558221.USD","BK4564","FOWF","LU2326559502.SGD","BK4516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669184485","title":"Actinogen Xanamia Pivotal Alzheimer’s Disease Trial Completes Final Patient Visit, with Topline Results on Track for November","url":"https://stock-news.laohu8.com/highlight/detail?id=2669184485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669184485?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:30","pubTimestamp":1790166600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA9K7DYM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ACW.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669170131","title":"Paradigm Biopharmaceuticals' Knee Osteoarthritis Study Fails to Reach Continuation Threshold","url":"https://stock-news.laohu8.com/highlight/detail?id=2669170131","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669170131?lang=en_us&edition=fundamental","pubTime":"2026-09-23 14:03","pubTimestamp":1790143392,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said the interim efficacy result for its phase 3 trial of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis did not reach the threshold required for the study to proceed, according to a Wednesday filing with the Australian bourse.Operational challenges resulted in a \"significant amount of missing data\" that impacted the interim analysis, which was conducted after about 50% of participants reached the day 112 primary efficacy endpoint, the company said.Paradigm is reviewing the available data to better understand the extent of the impact. It expects to disclose the financial and funding implications of the outcome by Sept. 28.The company said it is assessing the implications for its financial position and future operations, including a review of potential trial wind-down costs. It added that \"material uncertainty\" remains over the consequences of the trial outcome and the company's path forward.Paradigm shares will remain suspen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PAR.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669179100","title":"Prescient Therapeutics Raises Around AU$4.8 Million Via Share Purchase Plan, AU$1.2 Million in Shortfall Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669179100","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669179100?lang=en_us&edition=fundamental","pubTime":"2026-09-23 10:15","pubTimestamp":1790129735,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  raised around AU$4.8 million via its share purchase plan and around AU$1.2 million in the shortfall placement, according to a Wednesday Australian bourse filing.The issue price under the share purchase plan and the placement was AU$0.065 apiece. Around 18.5 million new shares are expected to be issued under the placement.The proceeds will provide additional funding for the continued development of its PTX-100 treatment candidate beyond the first dose optimization committee review.Its shares fell 2% in recent trading on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK4139","BK7067","LENZ","PTX.AU","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669176721","title":"Prescient Therapeutics Raises A$4.8 Million Via SPP, A$1.2 Million in Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669176721","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669176721?lang=en_us&edition=fundamental","pubTime":"2026-09-23 09:45","pubTimestamp":1790127905,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics Raises A$4.8 Million Via SPP, A$1.2 Million In PlacementSept 23 (Reuters)-Prescient Therapeutics LtdPTX.AX:RAISES A$4.8 MILLION VIA SPP AND A$1.2 MILLION IN PLACEMENTISSUE PRICE FOR PLACEMENT AND SPP SHARES SET AT A$0.065 PER SHAREFurther company coverage:PTX.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45E0YH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669317305","title":"Actinogen Medical Completes Final Patient Visit in Alzheimer's Therapy Trial; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669317305","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669317305?lang=en_us&edition=fundamental","pubTime":"2026-09-23 08:33","pubTimestamp":1790123638,"startTime":"0","endTime":"0","summary":"Actinogen Medical  said it completed the final patient visit in a phase 2b/3 clinical trial of its Xanamem oral therapy for Alzheimer's disease, according to a Wednesday filing with the Australian bourse.Top-line results for the trial remain on track for November, the company said.The company's shares jumped 5% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","ACW.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669736001","title":"Dimerix Receives AU$17 Million in Proceeds After Completing Initial Drawdown Under Non-Dilutive Funding Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2669736001","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669736001?lang=en_us&edition=fundamental","pubTime":"2026-09-23 08:17","pubTimestamp":1790122651,"startTime":"0","endTime":"0","summary":"Dimerix  confirmed that it completed an initial drawdown under its AU$34 million non-dilutive funding facility, receiving gross proceeds of AU$17 million, according to a Wednesday Australian bourse filing.The remaining AU$17 million is available for drawdown at the firm's election until March 31, 2027, subject to facility terms, the company said.It also confirmed that it was funded through to the delivery of the Action3 phase three trial of its DMX-200 treatment candidate in patients with focal segmental glomerulosclerosis, a rare kidney disease, and continued advancement of the phase two trial of DMX-652 in acute kidney injury.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7508","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669856173","title":"Prescient Therapeutics - Raises A$4.8 Mln Via Spp and A$1.2 Mln in Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669856173","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669856173?lang=en_us&edition=fundamental","pubTime":"2026-09-23 08:04","pubTimestamp":1790121883,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45E0YH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTX.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669173890","title":"Prescient Therapeutics - Issue Price for Placement and Spp Shares Set at A$0.065 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2669173890","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669173890?lang=en_us&edition=fundamental","pubTime":"2026-09-23 08:04","pubTimestamp":1790121883,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45E0YH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","PTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143640","title":"Immuron Submits Coffee Microcaps Conference Presentation##","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143640","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143640?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:03","pubTimestamp":1790071393,"startTime":"0","endTime":"0","summary":"Immuron submits Coffee Microcaps Conference presentation##Immuron published an investor presentation tied to CEO Steven Lydeamore’s Coffee Microcaps Conference slot on Sept. 22, 2026.Slides outline Tr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL4Sqgpx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669114086","title":"TC Energy Sells Mexico Natural Gas Pipeline to Esentia for $399.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114086","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669114086?lang=en_us&edition=fundamental","pubTime":"2026-09-22 15:53","pubTimestamp":1790063628,"startTime":"0","endTime":"0","summary":"TC Energy  has agreed to sell Energia Occidente de Mexico which owns the Guadalajara-Manzanilla Pipeline, to affiliates of Esentia Energy Development for 560 million Canadian dollars .The sale is expected to close in H1 2027, subject to closing conditions and regulatory approvals.The 313-kilometer pipeline moves up to 500 million cubic feet per day of natural gas between Guadalajara supply facilities to electricity plants and factories in Mexico's Colima and Jalisco states.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TPYP","BOIL","IE000HOSIQF4.USD","IE00BMG7P702.HKD","TRP.AU","MLPX","IE00BD4GTV84.USD","BK7508","BK7067","BK4566","IE00BMG7P587.USD","IE000WXP2NQ0.USD","TRP","IE00BMG7P926.USD","IE00BD4GTT62.SGD","BK4144","IE000SL1IH01.SGD","IE00BMG7P819.SGD","IE00BD4GTW91.USD","EINC","IE00BMG7P694.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669115427","title":"Dimerix Ltd-Waiver of Listing Rule 10.1 Granted","url":"https://stock-news.laohu8.com/highlight/detail?id=2669115427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669115427?lang=en_us&edition=fundamental","pubTime":"2026-09-22 13:46","pubTimestamp":1790055990,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUE3SH9TS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7067","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":-0.0219},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.0626},{"period":"1year","weight":0.105},{"period":"ytd","weight":0.037}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"name":"BK7508","nameEN":"BK7508"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pharmaceutical Companies(BK7508) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pharmaceutical Companies,BK7508,Pharmaceutical Companies股票,Pharmaceutical Companies股票老虎,Pharmaceutical Companies股票老虎国际,Pharmaceutical Companies行情,Pharmaceutical Companies股票行情,Pharmaceutical Companies股价,Pharmaceutical Companies股市,Pharmaceutical Companies股票价格,Pharmaceutical Companies股票交易,Pharmaceutical Companies股票购买,Pharmaceutical Companies股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pharmaceutical Companies(BK7508) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction